Genetics to epigenetics: targeting histone deacetylases in hormone receptor-positive metastatic breast cancer

Lancet Oncol. 2019 Jun;20(6):746-748. doi: 10.1016/S1470-2045(19)30279-7. Epub 2019 Apr 27.

Authors

Seth A Wander¹, Laura M Spring¹, Aditya Bardia²

Affiliations

¹ Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
² Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. Electronic address: bardia.aditya@mgh.harvard.edu.

PMID: 31036469
DOI: 10.1016/S1470-2045(19)30279-7

No abstract available

Publication types

Comment

MeSH terms

Androstadienes
Breast Neoplasms*
Double-Blind Method
Histone Deacetylase Inhibitors
Histone Deacetylases*
Humans
Postmenopause

Substances

Androstadienes
Histone Deacetylase Inhibitors
Histone Deacetylases
exemestane